Legal DealFolio - Endologix, Inc Convertible Senior Notes due 2018

Davis Polk advised Merrill Lynch, Pierce, Fenner & Smith Incorporated as sole book-running manager of the registered public offering by Endologix, Inc. of USD86.25 million aggregate principal amount of its 2.25% convertible senior notes due 2018 (which included the full exercise of the over-allotment option). In addition, Davis Polk advised Bank of America, N.A. as the counterparty to capped call transactions in connection with the convertible notes offering. Headquartered in Irvine, California, Endologix develops, manufactures, markets and sells innovative medical devices for the treatment of aortic disorders. Its principal product is a stent graft and accompanying delivery system, for the treatment of abdominal aortic aneurysms through minimally invasive endovascular repair. The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associates John K. Doulamis and Julian Russo. The equity derivatives team included partner Ray Ibrahim and associates Xiao Zhu and Robert Stewart. Partner Lucy W. Farr and associates Aaron M. Weil and Joseph Pahl provided tax advice. The intellectual property team included associates Bruce Rose-Innes and Nikita A. Tuckett. Counsel Loyti Cheng and associate Kevin J. Klesh provided environmental advice. Rosemarie Melendez was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.

Deal Date:	10-12-2013	Practice Area:	Debt Capital Markets
Deal Title:	Endologix, Inc Convertible Senior Notes due 2018	Industry:	Healthcare Equipment & Services
Description:	Davis Polk advised Merrill Lynch, Pierce, Fenner & Smith Incorporated as sole book-running manager of the registered public offering by Endologix, Inc. of USD86.25 million aggregate principal amount of its 2.25% convertible senior notes due 2018 (which included the full exercise of the over-allotment option). In addition, Davis Polk advised Bank of America, N.A. as the counterparty to capped call transactions in connection with the convertible notes offering. Headquartered in Irvine, California, Endologix develops, manufactures, markets and sells innovative medical devices for the treatment of aortic disorders. Its principal product is a stent graft and accompanying delivery system, for the treatment of abdominal aortic aneurysms through minimally invasive endovascular repair. The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associates John K. Doulamis and Julian Russo. The equity derivatives team included partner Ray Ibrahim and associates Xiao Zhu and Robert Stewart. Partner Lucy W. Farr and associates Aaron M. Weil and Joseph Pahl provided tax advice. The intellectual property team included associates Bruce Rose-Innes and Nikita A. Tuckett. Counsel Loyti Cheng and associate Kevin J. Klesh provided environmental advice. Rosemarie Melendez was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.
Financial Center:	New York	Value:	0.00-100.00
Advised Party:	Lead Manager	Law Firm	Davis Polk
Issuer Jurisdiction:	United States	Listing Jurisdiction:	United States
Classification:	Equity-Linked Securities Convertible Bonds	Lawyer	Deanna L Kirkpatrick

Practice Areas -

Debt Capital Markets Law Firms and Lawyers

Practice Areas - Debt Capital Markets Law Firms and Lawyers